Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a ...

Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Zepbound is a medicine you can obtain only by prescription, and it's typically used to address obesity and other ...

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...